{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:40:13Z","timestamp":1781494813869,"version":"3.54.1"},"reference-count":57,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Tumor-induced osteomalacia (TIO) due to fibroblast growth factor 23 (FGF23) overexpression is becoming recognized in patients with malignancy. The condition may be underdiagnosed, with a scarce medical literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To perform a meta-analysis of case reports to allow a better understanding of malignant TIO and its clinical implications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Full texts were selected according to strict inclusion criteria. All case reports were included where patients had hypophosphatemia, malignant TIO, and FGF23 blood levels. Thirty-two of 275 eligible studies (n = 34 patients) met inclusion criteria. A list of desired data was extracted and graded for methodological quality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Prostate adenocarcinoma (n = 9) were the most tumors reported. Twenty-five of 34 patients had a metastatic disease and a poor clinical outcome was reported for 15 of 28 patients. The median levels of blood phosphate and C-terminal FGF23 (cFGF23) were 0.40 mmol\/L and 788.5 RU\/mL, respectively. For most of patients, blood PTH was elevated or within range, and calcitriol levels were inappropriately low or normal. Alkaline phosphatase concentrations were increased for 20 of 22 patients. The cFGF23 values were significantly higher for patients with a poor clinical outcome when compared to other patients (1685 vs 357.5 RU\/mL). In case of prostate cancer, cFGF23 levels were significantly lower (429.4 RU\/mL) than for other malignancies (1007.5 RU\/mL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We report for the first time a detailed description of the clinical and biological characteristics of malignant TIO. In this context, FGF23 blood measurement would be of value for the diagnostic workup, prognostication, and follow-up of patients.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgad297","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T19:24:20Z","timestamp":1685129060000},"page":"3031-3040","source":"Crossref","is-referenced-by-count":8,"title":["Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports"],"prefix":"10.1210","volume":"108","author":[{"given":"Farouk","family":"Bouraima","sequence":"first","affiliation":[{"name":"Biochemistry and Molecular Genetics Department, University Hospital , 63000 Clermont-Ferrand , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7452-315X","authenticated-orcid":false,"given":"Vincent","family":"Sapin","sequence":"additional","affiliation":[{"name":"Biochemistry and Molecular Genetics Department, University Hospital , 63000 Clermont-Ferrand , France"},{"name":"Clermont Auvergne University, CNRS, INSERM, iGReD , 63000 Clermont-Ferrand , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Kahouadji","sequence":"additional","affiliation":[{"name":"Biochemistry and Molecular Genetics Department, University Hospital , 63000 Clermont-Ferrand , France"},{"name":"Clermont Auvergne University, CNRS, INSERM, iGReD , 63000 Clermont-Ferrand , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Eva","family":"Pickering","sequence":"additional","affiliation":[{"name":"Rheumatology Department, CHU Clermont-Ferrand , 63000 Clermont-Ferrand , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-7161","authenticated-orcid":false,"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[{"name":"Biostatistics unit (DRCI) Department, University Hospital , 63000 Clermont-Ferrand , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2707-4320","authenticated-orcid":false,"given":"Damien","family":"Bouvier","sequence":"additional","affiliation":[{"name":"Biochemistry and Molecular Genetics Department, University Hospital , 63000 Clermont-Ferrand , France"},{"name":"Clermont Auvergne University, CNRS, INSERM, iGReD , 63000 Clermont-Ferrand , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Oris","sequence":"additional","affiliation":[{"name":"Biochemistry and Molecular Genetics Department, University Hospital , 63000 Clermont-Ferrand , France"},{"name":"Clermont Auvergne University, CNRS, INSERM, iGReD , 63000 Clermont-Ferrand , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"issue":"10","key":"2023101816055225000_dgad297-B1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","article-title":"Tumor-induced osteomalacia","volume":"294","author":"Jan de Beur","year":"2005","journal-title":"JAMA"},{"issue":"7","key":"2023101816055225000_dgad297-B2","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/0192623317737469","article-title":"Pleiotropic actions of FGF23","volume":"45","author":"Erben","year":"2017","journal-title":"Toxicol Pathol"},{"issue":"2","key":"2023101816055225000_dgad297-B3","doi-asserted-by":"publisher","first-page":"F282","DOI":"10.1152\/ajprenal.90742.2008","article-title":"FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1","volume":"297","author":"Gattineni","year":"2009","journal-title":"Am J Physiol\u2014Ren Physiol"},{"issue":"9","key":"2023101816055225000_dgad297-B4","doi-asserted-by":"publisher","first-page":"e72816","DOI":"10.1371\/journal.pone.0072816","article-title":"FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues.","volume":"8","author":"Chanakul","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"2023101816055225000_dgad297-B5","first-page":"33","article-title":"Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years","volume":"16","author":"McCance","year":"1947","journal-title":"Q J Med"},{"key":"2023101816055225000_dgad297-B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bonr.2015.11.004","article-title":"Tumor induced osteomalacia secondary to anaplastic thyroid carcinoma: a case report and review of the literature","volume":"5","author":"Abate","year":"2016","journal-title":"Bone Rep"},{"issue":"2","key":"2023101816055225000_dgad297-B7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.5414\/CN110242","article-title":"Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer","volume":"95","author":"Abramson","year":"2021","journal-title":"Clin Nephrol"},{"issue":"4","key":"2023101816055225000_dgad297-B8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1053\/j.ajkd.2020.02.025","article-title":"FGF-23 mediated severe hypophosphatemia: a rare manifestation of malignancy","volume":"75","author":"Alawieh","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2023101816055225000_dgad297-B9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/2399369318776177","article-title":"Fibroblast growth factor 23\u2013secreting pancreaticobiliary malignancy","volume":"2","author":"Barta","year":"2018","journal-title":"J Onco-Nephrol"},{"issue":"2","key":"2023101816055225000_dgad297-B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5414\/CN110139","article-title":"Persistent urinary phosphate wasting in a patient with metastatic breast cancer: what's your diagnosis?","volume":"95","author":"Bhasin","year":"2021","journal-title":"Clin Nephrol"},{"issue":"6","key":"2023101816055225000_dgad297-B11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1053\/j.ajkd.2007.07.031","article-title":"Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia","volume":"50","author":"Cotant","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2023101816055225000_dgad297-B12","article-title":"Severe hypophosphatemia due to a FGF-23 producing, metastatic, aggressive tumor of unknown primary","volume":"35","author":"Dai-Ju","year":"2014","journal-title":"Endocr Rev"},{"key":"2023101816055225000_dgad297-B13","doi-asserted-by":"publisher","first-page":"bcr2015213954","DOI":"10.1136\/bcr-2015-213954","article-title":"Hypophosphataemia due to FGF-23 producing B cell non-Hodgkin's Lymphoma","volume":"2016","author":"Elderman","year":"2016","journal-title":"BMJ Case Rep"},{"issue":"5","key":"2023101816055225000_dgad297-B14","doi-asserted-by":"publisher","first-page":"B48","DOI":"10.1053\/j.ajkd.2014.01.135","article-title":"Oncogenic osteomalacia: renal phosphate wasting associated with metastatic breast cancer","volume":"63","author":"Garcha","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2023101816055225000_dgad297-B15","first-page":"618","article-title":"Hypophosphatemia and fibroblast growth factor 23 producing metastatic breast cancer","volume":"30","author":"Gutgarts","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2023101816055225000_dgad297-B16","article-title":"A case of androgen-and fibroblast growth factor 23-producing ovarian tumor","volume":"35","author":"Iguchi","year":"2014","journal-title":"Endocr Rev"},{"key":"2023101816055225000_dgad297-B17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1681\/ASN.20213210S1389b","article-title":"Severe hypophosphatemia induced by oncogenic osteomalacia","volume":"32","author":"Jalal","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2023101816055225000_dgad297-B18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ejim.2008.01.011","article-title":"Occult nasal sinus tumours causing oncogenic osteomalacia","volume":"19","author":"Kenealy","year":"2008","journal-title":"Eur J Intern Med"},{"key":"2023101816055225000_dgad297-B19","doi-asserted-by":"publisher","first-page":"bcr2014206590","DOI":"10.1136\/bcr-2014-206590","article-title":"Tumour-associated osteomalacia and hypoglycaemia in a patient with prostate cancer: is Klotho involved?","volume":"2014","author":"Latifyan","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"7","key":"2023101816055225000_dgad297-B20","doi-asserted-by":"publisher","first-page":"e229434","DOI":"10.1136\/bcr-2019-229434","article-title":"Metastatic prostate cancer presenting as tumour-induced osteomalacia","volume":"12","author":"Layman","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"3","key":"2023101816055225000_dgad297-B21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1210\/jc.2012-3473","article-title":"Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma","volume":"98","author":"Leaf","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2023101816055225000_dgad297-B22","first-page":"616","article-title":"Hypophosphatemia from a liver spindle cell tumor: A novel site for FGF23-related tumor-induced osteomalacia","volume":"30","author":"Leidner","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"2023101816055225000_dgad297-B23","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1210\/jc.2014-2120","article-title":"Ovarian cancer-related hypophosphatemic osteomalacia\u2013a case report","volume":"99","author":"Lin","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2023101816055225000_dgad297-B24","first-page":"620","article-title":"Use of anti-FGF-23 monoclonal antibody for the treatment of severe hypophosphatemia secondary to tumor-induced osteomalacia","volume":"30","author":"Lucas","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2023101816055225000_dgad297-B25","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00520-012-1474-z","article-title":"Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition","volume":"20","author":"Mak","year":"2012","journal-title":"Support Care Cancer"},{"issue":"1","key":"2023101816055225000_dgad297-B26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3892\/ol.2014.2081","article-title":"Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases","volume":"8","author":"Morimoto","year":"2014","journal-title":"Oncol Lett"},{"key":"2023101816055225000_dgad297-B27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clinbiochem.2022.03.006","article-title":"Hypophosphatemia related to a neuro-endocrine tumor of the pancreas: a case report","volume":"104","author":"Pickering","year":"2022","journal-title":"Clin Biochem"},{"issue":"6","key":"2023101816055225000_dgad297-B28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00223-011-9527-8","article-title":"Hypophosphatemia related to paraneoplastic Cushing syndrome in prostate cancer: cure after bilateral adrenalectomy","volume":"89","author":"Ramon","year":"2011","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2023101816055225000_dgad297-B29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1210\/js.2018-00010","article-title":"Fibroblast growth factor 23-induced hypophosphatemia in acute leukemia","volume":"2","author":"Reinert","year":"2018","journal-title":"J Endocr Soc"},{"issue":"8","key":"2023101816055225000_dgad297-B30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/RLU.0b013e3180a1ad1d","article-title":"Tumor-induced osteomalacia: a case of diagnostic dilemma","volume":"32","author":"Robertson","year":"2007","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2023101816055225000_dgad297-B31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.17925\/EE.2016.12.02.104","article-title":"Tumour-induced osteomalacia secondary to a sarcoma","volume":"12","author":"Rodriguez-Velver","year":"2016","journal-title":"Eur Endocrinol"},{"issue":"1","key":"2023101816055225000_dgad297-B32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40200-019-00398-y","article-title":"Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature","volume":"18","author":"Savva","year":"2019","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"2023101816055225000_dgad297-B33","doi-asserted-by":"publisher","first-page":"11A","DOI":"10.1038\/labinvest.2015.3","article-title":"FGF23 associated oncogenic hypophosphatemia\/osteomalacia in an autopsy case of pulmonary small cell carcinoma with liver metastasis","volume":"95","author":"Sauder","year":"2015","journal-title":"United States Canad Acad Pathol"},{"issue":"5","key":"2023101816055225000_dgad297-B34","doi-asserted-by":"crossref","first-page":"A104","DOI":"10.1053\/j.ajkd.2014.01.360","article-title":"Hypophosphatemia secondary to tumor induced osteomalacia in prostate cancer","volume":"63","author":"Sinnakirouchenan","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2023101816055225000_dgad297-B35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13193-021-01449-8","article-title":"Metastatic malignant phosphaturic mesenchymal tumor of mandibular alveolus: a rare case report and review of literature","volume":"13","author":"Thakur","year":"2022","journal-title":"Indian J Surg Oncol"},{"issue":"3","key":"2023101816055225000_dgad297-B36","article-title":"Hypophosphatemia in metastatic prostate carcinoma: case report","volume":"32","author":"Tloczkowski","year":"2011","journal-title":"Endocr Rev"},{"issue":"5","key":"2023101816055225000_dgad297-B37","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1159\/000516390","article-title":"A case of hypophosphatemia due to oncogenic osteomalacia in a patient with natural killer T-cell lymphoma","volume":"46","author":"Zheng","year":"2021","journal-title":"Kidney Blood Press Res"},{"issue":"14-15","key":"2023101816055225000_dgad297-B38","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.clinbiochem.2011.07.013","article-title":"Tumor-induced osteomalacia: the tumor may stay hidden!","volume":"44","author":"van der Rest","year":"2011","journal-title":"Clin Biochem"},{"issue":"3","key":"2023101816055225000_dgad297-B39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/joim.13593","article-title":"Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia","volume":"293","author":"Jan de Beur","year":"2023","journal-title":"J Intern Med"},{"key":"2023101816055225000_dgad297-B40","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"2023101816055225000_dgad297-B41","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid-Based Med"},{"issue":"3","key":"2023101816055225000_dgad297-B42","first-page":"1871","article-title":"Tumor-induced osteomalacia","volume":"7","author":"Kumar","year":"2015","journal-title":"Transl Endocrinol Metab"},{"issue":"9","key":"2023101816055225000_dgad297-B43","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1210\/jc.2012-1811","article-title":"Biological variability of plasma intact and C-terminal FGF23 measurements","volume":"97","author":"Smith","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023101816055225000_dgad297-B44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int"},{"key":"2023101816055225000_dgad297-B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2019.03.002","article-title":"FGF23: clinical usefulness and analytical evolution","volume":"66","author":"Fauconnier","year":"2019","journal-title":"Clin Biochem"},{"issue":"5","key":"2023101816055225000_dgad297-B46","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00223-017-0307-y","article-title":"Evaluation of a new fully automated assay for plasma intact FGF23","volume":"101","author":"Souberbielle","year":"2017","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2023101816055225000_dgad297-B47","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s00223-022-00987-9","article-title":"The measurement and interpretation of fibroblast growth factor 23 (FGF23) concentrations","volume":"112","author":"Heijboer","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"2023101816055225000_dgad297-B48","doi-asserted-by":"publisher","first-page":"5172131","DOI":"10.1155\/2021\/5172131","article-title":"TIO associated with hyperparathyroidism: a rarity, a rule, or a novel HPT-PMT syndrome\u2014a case study with literature review","volume":"2021","author":"Salim","year":"2021","journal-title":"Case Rep Endocrinol"},{"issue":"10","key":"2023101816055225000_dgad297-B49","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2023101816055225000_dgad297-B50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/2048872613494025","article-title":"FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock","volume":"2","author":"P\u00f6ss","year":"2013","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"3","key":"2023101816055225000_dgad297-B51","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/ijms20030695","article-title":"Levels of circulating fibroblast growth factor 23 (FGF23) and prognosis in cancer patients with bone metastases","volume":"20","author":"Mansinho","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2023101816055225000_dgad297-B52","doi-asserted-by":"publisher","first-page":"601006","DOI":"10.3389\/fcell.2020.601006","article-title":"Role of fibroblast growth factor 23 (FGF23) and \u03b1Klotho in cancer","volume":"8","author":"Ewendt","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"19","key":"2023101816055225000_dgad297-B53","doi-asserted-by":"publisher","first-page":"17291","DOI":"10.18632\/oncotarget.4174","article-title":"FGF23 promotes prostate cancer progression","volume":"6","author":"Feng","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"2023101816055225000_dgad297-B54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1442-2042.2008.02175.x","article-title":"Neuroendocrine differentiation in the progression of prostate cancer","volume":"16","author":"Komiya","year":"2009","journal-title":"Int J Urol"},{"issue":"6","key":"2023101816055225000_dgad297-B55","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"2023101816055225000_dgad297-B56","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"23","key":"2023101816055225000_dgad297-B57","doi-asserted-by":"publisher","first-page":"19647","DOI":"10.18632\/oncotarget.3794","article-title":"FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells","volume":"6","author":"Suvannasankha","year":"2015","journal-title":"Oncotarget"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad297\/50516655\/dgad297.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/3031\/52218004\/dgad297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/3031\/52218004\/dgad297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T05:45:20Z","timestamp":1729489520000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/11\/3031\/7180823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,5,26]]},"published-print":{"date-parts":[[2023,10,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad297","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,5,26]]}}}